1. Signaling Pathways
  2. GPCR/G Protein
  3. GPCR19


GPCR19 (G-protein coupled receptor 19, GPBAR1) is a protein that in humans is encoded by the GPBAR1 gene. This gene encodes a member of the G protein-coupled receptor (GPCR) superfamily. GPCR19 functions as a cell surface receptor for bile acids. Treatment of cells expressing this GPCR with bile acids induces the production of intracellular cAMP, activation of a MAP kinase signaling pathway, and internalization of the receptor. The receptor is implicated in the suppression of macrophage functions and regulation of energy homeostasis by bile acids. One effect of this receptor is to activate deiodinases which convert the prohormone thyroxine (T4) to the active hormone triiodothyronine (T3). T3 in turn activates the thyroid hormone receptor which increases metabolic rate.

GPCR19 Related Products (13):

Cat. No. Product Name Effect Purity
  • HY-15677
    INT-777 Agonist ≥98.0%
    INT-777 is a potent TGR5 agonist with an EC50 of 0.82 μM.
  • HY-N0593
    Deoxycholic acid Activator ≥98.0%
    Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.
  • HY-111534
    SBI-115 Antagonist 99.51%
    SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5.
  • HY-B0575
    Triamterene Inhibitor 99.98%
    Triamterene blocks epithelial Na+ channel (ENaC) in a voltage-dependent manner, which used as a mild diuretic. Triamterene as an inhibitor of the TGR5 receptor.
  • HY-N0593A
    Deoxycholic acid sodium salt Activator ≥98.0%
    Deoxycholic acid sodium salt is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.
  • HY-14229
    TGR5 Receptor Agonist Agonist 99.85%
    TGR5 Receptor Agonist (CCDC), a potent TGR5(GPCR19) agonist, shows improved potency in the U2-OS cell assay (pEC50=6.8) and in melanophore cells (pEC50=7.5).
  • HY-12434
    INT-767 Agonist ≥98.0%
    INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC50s of 30 and 630 nM, respectively.
  • HY-N0169
    Hyodeoxycholic acid Agonist ≥99.0%
    Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHO cells.
  • HY-101274
    BAR501 Agonist ≥98.0%
    BAR501 is a potent and selective agonist of GPBAR1 with an EC50 of 1 μM.
  • HY-102016
    SB756050 Agonist 99.32%
    SB756050 is a selective TGR5 agonist. SB756050 has the potential for type 2 diabetes treatment.
  • HY-101273
    BAR502 Agonist ≥98.0%
    BAR502 is a dual FXR and GPBAR1 agonist with IC50 values of 2 μM and 0.4 μM, respectively.
  • HY-15677A
    INT-777 R-enantiomer Agonist
    INT-777 (R-enantiomer) is the R-enantiomer of INT-777, with EC50 of 4.79 μM for TGR5, and less potent than INT-777.
  • HY-110173
    TC-G 1005 Agonist 99.91%
    TC-G 1005 is a potent, selective and orally active agonist of the BA receptor Takeda G protein-coupled receptor 5 (TGR5), with EC50s of 0.72 and 6.2 nM for hTGR5 and mTGR5, respectively. TC-G 1005 can reduce glucose levels in vivo.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.